{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:57:16Z","timestamp":1790870236363,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"High Innovation Plan","award":["G202531207"],"award-info":[{"award-number":["G202531207"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFC2510500"],"award-info":[{"award-number":["2024YFC2510500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1103300"],"award-info":[{"award-number":["2022YFA1103300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major Program of the National Natural Science Foundation of China","award":["82293630"],"award-info":[{"award-number":["82293630"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Severe aplastic anemia (SAA) is a life-threatening hematological disorder, and the optimal treatment for patients aged \u226540 years remains controversial. This retrospective study aims to conduct a comparative analysis of the efficacy of immunosuppressive therapy (IST) versus haploidentical hematopoietic stem cell transplantation (haplo-HSCT) specifically in elderly patients. To minimize selection bias, propensity score matching (PSM) was performed to pair samples based on age and Eastern Cooperative Oncology Group score, thereby addressing treatment responses and survival outcomes while ensuring balanced baseline characteristics between the 2 groups. The study reveals that while overall survival (OS) rates were similar (69.6%\u2009\u00b1\u200913.3% vs. 68.6%\u2009\u00b1\u200912.1%, P\u2009=\u20090.80), haplo-HSCT significantly outperformed IST in terms of failure-free survival (FFS) rates (68.7%\u2009\u00b1\u200912.1% vs. 46.5%\u2009\u00b1\u200920.2%, P\u2009=\u20090.025). Multivariate Cox regression analysis confirmed that treatment modality and disease severity were independent predictors of FFS. These findings support haplo-HSCT as a viable first-line treatment option for appropriately selected elderly SAA patients, providing evidence for treatment options in patients with SAA aged 40 and above.<\/jats:p>","DOI":"10.1093\/stcltm\/szag076","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:45:48Z","timestamp":1785843948000},"source":"Crossref","is-referenced-by-count":0,"title":["Haploidentical HSCT vs immunosuppressive therapy for severe aplastic anemia in patients aged 40-65 years: a retrospective comparative study"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9192-6885","authenticated-orcid":false,"given":"Sheng-nan","family":"Gao","sequence":"first","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-song","family":"Jia","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6643","authenticated-orcid":false,"given":"Xiao-jun","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-yuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5047-9249","authenticated-orcid":false,"given":"Ting-ting","family":"Han","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-xia","family":"Fu","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"He","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-zhi","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-dong","family":"Mo","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-qian","family":"Sun","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-hui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-ping","family":"Xu","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-li","family":"Xu","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026100111161085000_szag076-B1","doi-asserted-by":"publisher","first-page":"1425076","DOI":"10.3389\/fimmu.2024.1425076","article-title":"Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed\/refractory severe aplastic anemia","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"2026100111161085000_szag076-B2","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.2147\/IJGM.S310844","article-title":"Hematopoietic stem-cell transplantation versus immunosuppressive therapy in patients with adult acquired severe aplastic anemia: a cost-effectiveness analysis","volume":"14","author":"Zhang","year":"2021","journal-title":"Int J Gen Med"},{"key":"2026100111161085000_szag076-B3","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41409-024-02377-1","article-title":"First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study","volume":"59","author":"Liu","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"2026100111161085000_szag076-B4","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00277-025-06335-9","article-title":"The efficacy of immunosuppressive therapy with or without thrombopoietin receptor agonist in elderly patients with severe aplastic anemia","volume":"104","author":"Li","year":"2025","journal-title":"Ann Hematol"},{"key":"2026100111161085000_szag076-B5","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ajh.27611","article-title":"Elderly patients with aplastic anemia: treatment patterns and outcomes in the real world","volume":"100","author":"Fattizzo","year":"2025","journal-title":"Am J Hematol"},{"key":"2026100111161085000_szag076-B6","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.scib.2026.01.057","article-title":"Who is the best allogeneic hematopoietic stem cell transplant donor for severe aplastic anemia? Data from the Chinese bone marrow transplantation registry group (CBMTRG)","volume":"71","author":"Xu","year":"2026","journal-title":"Sci Bull (Beijing)"},{"key":"2026100111161085000_szag076-B7","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1016\/S2352-3026(22)00206-X","article-title":"Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial","volume":"9","author":"Dezern","year":"2022","journal-title":"Lancet Haematol"},{"key":"2026100111161085000_szag076-B8","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/s41409-025-02633-y","article-title":"Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic anemia: a study of the SAAWP EBMT","volume":"60","author":"Montoro","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"2026100111161085000_szag076-B9","doi-asserted-by":"publisher","first-page":"217594","DOI":"10.1016\/j.canlet.2025.217594","article-title":"Comparable survival outcomes in HLA-matched and haploidentical hematopoietic stem cell transplantation for severe aplastic anemia patients aged 40-50: a CBMTR registry-based propensity score matching analysis over the last decade","volume":"621","author":"Xu","year":"2025","journal-title":"Cancer Lett"},{"key":"2026100111161085000_szag076-B10","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.3324\/haematol.2023.284581","article-title":"The outcome of allogeneic hematopoietic stem cell transplantation among elderly patients with severe aplastic anemia and a predictive model from the Chinese Blood and Marrow Transplant Registry Group","volume":"109","author":"Xu","year":"2024","journal-title":"Haematologica"},{"key":"2026100111161085000_szag076-B11","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/s41409-025-02617-y","article-title":"Clinical outcomes of offspring and matched unrelated donor transplants in relapsed or refractory severe aplastic anemia patients aged 40-50: a retrospective analysis from the CBMTR over the past decade","volume":"60","author":"Zhao","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"2026100111161085000_szag076-B12","doi-asserted-by":"publisher","first-page":"e70359","DOI":"10.1111\/ctr.70359","article-title":"The eastern cooperative oncology group score rather than donor type impacts clinical outcomes of allogeneic hematopoietic stem cell transplantation in severe aplastic anemia patients aged 51-60 years: a retrospective study from the Chinese blood and marrow transplant registry","volume":"39","author":"Zhao","year":"2025","journal-title":"Clin Transplant"},{"key":"2026100111161085000_szag076-B13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/bmt.2016.223","article-title":"Immunosuppressive therapy versus alternative donor hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched familial donor","volume":"52","author":"Choi","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2026100111161085000_szag076-B14","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1182\/blood-2007-08-099168","article-title":"J Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia","volume":"111","author":"Kosaka","year":"2008","journal-title":"Blood"},{"key":"2026100111161085000_szag076-B15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/bjh.14225","article-title":"Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study","volume":"175","author":"Xu","year":"2016","journal-title":"Br J Haematol"},{"key":"2026100111161085000_szag076-B16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-017-0398-y","article-title":"Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant","volume":"10","author":"Xu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"2026100111161085000_szag076-B17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/sj.bmt.1705445","article-title":"Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies","volume":"38","author":"Huang","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"2026100111161085000_szag076-B18","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/bmt.2012.79","article-title":"A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia","volume":"47","author":"Xu","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"2026100111161085000_szag076-B19","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/CM9.0000000000003917","article-title":"Chinese society of hematology clinical practice guidelines for the comprehensive management of allogeneic hematopoietic stem cell transplantation in patients with severe aplastic anemia","volume":"139","author":"Xu","year":"2026","journal-title":"Chin Med J (Engl)"},{"key":"2026100111161085000_szag076-B20","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"2026100111161085000_szag076-B21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"key":"2026100111161085000_szag076-B22","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"2026100111161085000_szag076-B23","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026100111161085000_szag076-B24","doi-asserted-by":"publisher","first-page":"614965","DOI":"10.3389\/fonc.2021.614965","article-title":"Comparisons between frontline therapy and a combination of eltrombopag plus immunosuppression therapy and human leukocyte antigen-haploidentical hematopoietic stem cell transplantation in patients with severe aplastic anemia: a systematic review","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"2026100111161085000_szag076-B25","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/s41409-018-0410-3","article-title":"Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia","volume":"54","author":"Xu","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"2026100111161085000_szag076-B26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-022-01324-1","article-title":"Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study","volume":"15","author":"Liu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026100111161085000_szag076-B27","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1182\/bloodadvances.2025018285","article-title":"Comparable outcomes of HSCT up-front and after failure of IST in pediatric aplastic anemia in recent years","volume":"10","author":"Andresen","year":"2026","journal-title":"Blood Adv"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/15\/10\/szag076\/71560759\/szag076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/15\/10\/szag076\/71560759\/szag076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:18:17Z","timestamp":1790867897000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/doi\/10.1093\/stcltm\/szag076\/8859199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/stcltm\/szag076","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,18]]},"article-number":"szag076"}}